Acquisition

Pulmatrix nears year-end merger with Eos as cash falls to $1.4M

What's the deal? Pulmatrix expects to close its all-stock merger with privately held Eos SENOLYTIXDealroom has a profile for this one. Try Dealroom → by the end of November 2026, with Eos holders and financing participants set to own about 94% of the combined company. The deal, announced March 26, 2026, would hand Eos control and make its drug program the business of the merged entity. Terms were undisclosed.

What does each side do? Pulmatrix is a Nasdaq-listed developer of inhaled therapeutics built on its iSPERSE technology. Eos is advancing MitoXcel, a gerotherapeutic peptide platform targeting mitochondrial dysfunction in aging-related diseases.

By the numbers: Pulmatrix posted a net loss of $1.2 million, or $0.34 per share, in the third quarter, up from $0.9 million a year earlier. The increase stemmed from merger-related legal and professional costs. For the nine months, the loss narrowed to $3.4 million from $4.2 million.

What could go wrong? Closing still hinges on Nasdaq approval of the new shares and a reverse stock split that shareholders cleared on October 26, 2026. Cash and equivalents fell to $1.4 million at quarter-end, plus $0.7 million restricted, from $4.1 million at the start of the period. Pulmatrix flagged substantial doubt about its ability to continue as a going concern.

Why now? The transaction is Pulmatrix's route back to compliance with Nasdaq's $2.5 million stockholders' equity rule. The agreement includes $19 million in concurrent private financings, intended partly to lift equity above that threshold and fund Eos's development program.

What's the endgame? With clinical work on hold, Pulmatrix is trying to out-license or monetise its assets. Its iSPERSE portfolio held about 143 granted patents and 47 pending applications at quarter-end. Partner CiplaDealroom has a profile for this one. Try Dealroom → is set to begin a Phase 3 trial of PUR1900 in India in 2026, on which Pulmatrix would earn 2% royalties outside the US.

The signal: This is less a merger than a reverse takeover — a cash-strapped, listed shell giving a private biotech a public home. For investors, the shift from inhaled therapeutics to aging science is near-total, and value now rides on whether the deal closes and Eos delivers.

Read more: minichart.com.sg

Image credit: Generated with Gemini

More top stories